Novartis India Ltd
- Market Cap ₹ 2,617 Cr.
- Current Price ₹ 1,060
- High / Low ₹ 1,248 / 745
- Stock P/E 25.9
- Book Value ₹ 318
- Dividend Yield 2.36 %
- ROCE 17.0 %
- ROE 13.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 58.5% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 82.3%
Cons
- The company has delivered a poor sales growth of -4.06% over past five years.
- Company has a low return on equity of 12.7% over last 3 years.
- Earnings include an other income of Rs.42.0 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
859 | 870 | 690 | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 335 | 356 | |
861 | 874 | 656 | 631 | 570 | 478 | 426 | 355 | 373 | 314 | 270 | 265 | |
Operating Profit | -1 | -4 | 34 | 25 | -6 | 12 | 12 | 27 | 27 | 65 | 65 | 91 |
OPM % | -0% | -0% | 5% | 4% | -1% | 2% | 3% | 7% | 7% | 17% | 19% | 26% |
95 | 101 | 207 | 71 | 172 | 78 | 36 | 33 | -17 | 58 | 62 | 42 | |
Interest | 0 | 0 | 0 | 1 | 6 | 2 | 6 | 8 | 5 | 2 | 1 | 1 |
Depreciation | 4 | 4 | 3 | 4 | 3 | 3 | 13 | 12 | 10 | 6 | 3 | 2 |
Profit before tax | 90 | 93 | 237 | 92 | 158 | 86 | 29 | 40 | -4 | 115 | 123 | 130 |
Tax % | -10% | 15% | 16% | 38% | 50% | 40% | 65% | 48% | -3% | 10% | 31% | 23% |
99 | 79 | 198 | 57 | 78 | 52 | 10 | 21 | -4 | 103 | 85 | 101 | |
EPS in Rs | 30.83 | 24.75 | 62.04 | 20.33 | 31.74 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.50 | 40.87 |
Dividend Payout % | 32% | 40% | 16% | 49% | 32% | 48% | 245% | 118% | -663% | 113% | 72% | 61% |
Compounded Sales Growth | |
---|---|
10 Years: | -9% |
5 Years: | -4% |
3 Years: | -4% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | 3% |
5 Years: | 58% |
3 Years: | 35% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | 3% |
5 Years: | 14% |
3 Years: | 16% |
1 Year: | -4% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 13% |
Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
Reserves | 945 | 986 | 1,178 | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 773 |
0 | 0 | 0 | 0 | 0 | 0 | 68 | 62 | 24 | 22 | 7 | 5 | |
241 | 244 | 239 | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 158 | |
Total Liabilities | 1,202 | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 |
8 | 8 | 6 | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 5 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1,194 | 1,238 | 1,426 | 1,144 | 1,106 | 967 | 1,001 | 938 | 934 | 964 | 918 | 943 | |
Total Assets | 1,202 | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-5 | -60 | 57 | -41 | 161 | -194 | -23 | -69 | 39 | 45 | 113 | 75 | |
22 | 719 | -630 | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | -3 | |
-38 | -38 | -39 | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | -64 | |
Net Cash Flow | -20 | 622 | -612 | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 | 7 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 33 | 35 | 27 | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 | 41 |
Inventory Days | 96 | 103 | 92 | 104 | 84 | 111 | 117 | 119 | 117 | 99 | 82 | 74 |
Days Payable | 100 | 98 | 89 | 87 | 158 | 168 | 145 | 137 | 148 | 108 | 112 | 93 |
Cash Conversion Cycle | 29 | 40 | 30 | 40 | -45 | -23 | 3 | 19 | 10 | 26 | 15 | 22 |
Working Capital Days | 353 | 6 | -35 | -14 | -99 | 7 | 9 | 75 | -18 | -33 | -57 | -43 |
ROCE % | 10% | 9% | 22% | 9% | 17% | 12% | 5% | 6% | 6% | 15% | 16% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3h - In relation to the information published in the newspaper to inform the members regarding the proposed 77th Annual General Meeting (''AGM'') of the company to …
-
The Intimation Is Submitted To Update That Communication Is Sent On Email To The Shareholders Regarding The Tax Deduction At Source On The Dividend If Approved At The Ensuing Annual General Meeting To Be Held On Thursday, July 31, 2025
4h - Novartis informs shareholders about TDS on Rs.25 dividend for FY24-25, payable post AGM on July 31, 2025.
-
Board Meeting Intimation for Intimation Of The Meeting Of The Board Of The Company For The Approval Of Quarterly Unaudited Financial Results For The Quarter Ended June 30, 2025.
1d - Board meeting on July 29 to approve Q1 June 30, 2025 results; trading window closed from July 1.
-
Closure of Trading Window
1d - Board meeting on July 29 to approve Q1 2025 results; trading window closed from July 1.
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 16 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business
The company is primarily engaged in the pharmaceutical business in the area of pain management, organ transplantation, neuroscience, etc. [1]